MARS ROSS POTTETO 27 SEP 2006

PATENT ATTORNEY DOCKET NO. 50318/012001

Certificate of Mailing: Date of Deposit: September 21,2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeremy Waterman

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Barbara Ensoli et al.

Confirmation No.: Not yet assigned

Serial No.:

10/577,974

Art Unit:

Not yet assigned

Filed:

May 3, 2006

Examiner:

Not yet assigned

Customer No.:

21559

Title:

Use of Microparticles for Antigen Delivery

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

DE 30 48 883 and DE 101 18 852 are in the German language. Applicants submit

that English language equivalents of these applications are U.S. Patent No. 4,415,700 and U.S. Application No. 2004/0062815, respectively.

EP 0 240 424 is in the French language. Applicants submit an English language translation of the abstract as the concise explanation of the relevance of this document.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: September 21,2006

Susan M. Michaud, Ph.D.

Reg. No. 42,885

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50318/012001	
(MODIFIED)		Serial No.	10/577,974	
IN ITO DA A TIA		Applicant	Barbara Ensoli et al.	
STATEMEN	ON DISCLOSURE T BY APPLICANT	Filing Date	May 3, 2006	
(Use several sheets if necessary)		Group	Not yet assigned	
(37 C.F.R. § 1.98(b))		IDS Filed	September 21, 2006	

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,415,700	11/15/83	Batz et al.			
	5,334,394	08/02/94	Kossovsky et al.			
	2004/0062815	04/01/04	Fricker et al.			
	FORE	EIGN PATENT	OR PUBLISHED FOREIGN PATENT A	PPLICATION	ON	
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	DE 30 48 883	07/15/82	DE			,
	DE 101 18 852	10/31/02	DE			
	EP 0 240 424	03/27/87	EP			
	WO 95/26376	10/05/95	WIPO			
	WO 00/12065	03/09/00	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
Alpar et al., "New Strategies in Vaccine Delivery," S.T.P. Pharma. Sci. 10:269-278, 2000.						
Betti et al., "Characterization of HIV-1 Tat Proteins Mutated in the Transactivation Domain for Prophylatic and Therapeutic Application," Vaccine 19:3408-3419, 2001.						
Caputo et al., "Immunization with Low Doses of HIV-1 tat DNA Delivered by Novel Cationic Block Copolymers Induces CTL Responses Against Tat," Vaccine 21:1103-1111, 2003.						
Caputo et al., "Novel Biocompatible Anionic Polymeric Microspheres for the Delivery of the HIV-1 Tat Protein for Vaccine Application," Vaccine 22:2910-2924, 2004.						
Caselli et al., "DNA Immunization with HIV-1 tat Mutated in the trans Activation Domain Induces Humoral and Cellular Immune Responses Against Wild-Type Tat," J. Immunol. 162:5631-5638, 1999.						
	Chang et al., "HIV-1 Tat Protein Exits from Cells Via a Leaderless Secretory Pathway and Binds to Extracellular Matrix-Associated Heparan Sulfate Proteogylcans Through its Basic Region," Aids 11:1421-1431, 1997.					
	Dinnella et al., "Immobilization and Reactivity of Enzymes on Functional Particles Prepared by Dispersion Polymerization," Macromol. Rapid Commun. 15:909-915, 1994.				ispersion	

CV	A A	AIN		
EX	MI	/III	ИC	Г

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50318/012001	
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/577,974	
	N. D. CO. CO. LD.	Applicant	Barbara Ensoli et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	May 3, 2006	
		Group	Not yet assigned	
(37 C.F.R. § 1.98(b))		IDS Filed	September 21, 2006	

Ensoli et al., "Release, Uptake, and Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein on Cell Growth and Viral Transactivation," J. Virol. 67:277-287, 1993.
Ensoli et al., "Synergy Between Basic Fibroblast Growth Factor and HIV-1 Tat Protein in Induction of Kaposi's Sarcoma," Nature 371:674-680, 1994.
Fanales-Belasio et al., "Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses," J. Immunol. 168:197-206, 2002.
Laus et al., "Microspheres with Hydrophilic and Protein-Friendly Surface as Protein Delivery Systems Prepared by Dispersion Polymerization," J. Controlled Release 72:225-309, 2001.
Micheletti et al., "Identification of Cytotoxic T Lymphocyte Epitopes of Human Herpesvirus 8," Immunol. 106:395-403, 2002.
Nedrud et al., "Adjuvants and the Mucosal Immune System," in <u>Topics in Vaccine Adjuvant Research</u> , CRC 51-67, 1991.
 Nugent et al., "Design and Delivery of Non-Parenteral Vaccines," J. Clin. Pharm. Therap. 23:257-285, 1998.
O'Hagan et al., "Poly(lactide-co-glycolide) Microparticles for the Development of Single-Dose Controlled-Release Vaccines," Adv. Drug Deliv. Rev. 32:225-246, 1998.
O'Hagan, "Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration," J. Pharm. Pharmacol. 49:1-10, 1997.
Sparnacci et al., "Core-Shell Microspheres by Dispersion Polymerization as Drug Delivery Systems," Macromol. Chem. Phys. 203:1364-1369, 2002.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.